Department of Cardiology & Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura City, Japan.
Department of Cardiology & Catheterization Laboratories, Shonan Kamakura General Hospital, Kamakura City, Japan; Heart and Lung Center, Helsinki University Central Hospital, Helsinki University, Helsinki, Finland.
Am J Cardiol. 2023 Mar 15;191:14-22. doi: 10.1016/j.amjcard.2022.12.002. Epub 2023 Jan 7.
The impact of mild paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) remains controversial. We evaluated the impact of mild PVR after TAVI on long-term clinical outcomes. We included patients who underwent TAVI for severe symptomatic aortic stenosis between December 2008 and June 2019 at 2 international centers and compared all-cause death between the group with mild PVR (group 1) and the group with none or trace PVR (group 2). PVR was categorized using a 3-class grading scheme, and patients with PVR ≧ moderate and those who were lost to follow-up were excluded. This retrospective analysis included 1,404 patients (mean age 81.7 ± 6.5 years, 58.0% women). Three hundred fifty eight patients (25.5%) were classified into group 1 and 1,046 patients (74.5%) into group 2. At baseline, group 1 was older and had a lower body mass index, worse co-morbidities, and more severe aortic stenosis. To account for these differences, propensity score matching was performed, resulting in 332 matched pairs. Within these matched groups, during a mean follow-up of 3.2 years, group 1 had a significantly lower survival rate at 5 years (group 1: 62.0% vs group 2: 68.0%, log-rank p = 0.029, hazard ratio: 1.41 [95% confidence interval: 1.04 to 1.91]). In the matched cohort, patients with mild PVR had a significant 1.4-fold increased risk of mortality at 5 years after TAVI compared with those with none or trace PVR. Further studies with more patients are needed to evaluate the impact of longer-term outcomes.
经导管主动脉瓣置换术(TAVI)后轻度瓣周漏(PVR)的影响仍存在争议。我们评估了 TAVI 后轻度 PVR 对长期临床结局的影响。我们纳入了 2008 年 12 月至 2019 年 6 月在 2 个国际中心接受 TAVI 治疗的严重症状性主动脉瓣狭窄患者,并比较了轻度 PVR 组(第 1 组)和无或微量 PVR 组(第 2 组)的全因死亡率。使用 3 级分级方案对 PVR 进行分类,并排除 PVR≧中度的患者和失访患者。这项回顾性分析纳入了 1404 例患者(平均年龄 81.7±6.5 岁,58.0%为女性)。358 例(25.5%)患者被分为第 1 组,1046 例(74.5%)患者被分为第 2 组。在基线时,第 1 组年龄更大,体重指数更低,合并症更严重,且主动脉瓣狭窄更严重。为了考虑到这些差异,进行了倾向评分匹配,得到 332 对匹配组。在这些匹配组中,平均随访 3.2 年后,第 1 组的 5 年生存率显著较低(第 1 组:62.0%,第 2 组:68.0%,log-rank p=0.029,风险比:1.41[95%置信区间:1.04 至 1.91])。在匹配队列中,与无或微量 PVR 相比,TAVI 后 5 年轻度 PVR 患者的死亡风险显著增加 1.4 倍。需要更多患者的进一步研究来评估长期结局的影响。